Boutros A, Wang J
Department of Anesthesiology, State University of New York Health Science Center at Brooklyn, USA.
J Pharmacol Exp Ther. 1995 Dec;275(3):1148-56.
The frequency of chronic hypertension among cardiac surgery patients implies that experimental therapies that protect normotensive myocardium will be more clinically relevant if they also protect chronically hypertensive myocardium. We tested the effectiveness of three experimental therapies that protect normotensive myocardium from ischemic injury in both normotensive (NTR) and spontaneously hypertensive (SHR) isolated Sprague-Dawley rat hearts. Post-ischemic recovery of ATP, left ventricular end diastolic pressure, developed pressure, negative and positive left ventricular dP/dt (-dP/dt and +dP/dt) and coronary flow (CF) were compared in ischemically preconditioned, adenosine-pretreated, bethanechol-pretreated and untreated NTR and SHR isolated rat hearts. The effect of time on our preparation was evaluated by comparison to NTR and SHR hearts maintained in vitro for equal duration but not subjected to an ischemic insult (N = 7, all groups). Preconditioning, adenosine and bethanechol significantly improved recovery of ATP, left ventricular end diastolic pressure, developed pressure, -dP/dt, +dP/dt and coronary flow in both NTR and SHR hearts (P < 0.001 vs. untreated, all comparisons). Although recovery was not so pronounced in SHR hearts, these results suggest that experimental therapies that protect normotensive myocardium also protect chronically hypertensive myocardium. The effect of adenosine and that of ischemic preconditioning were nearly identical, and both treatments were significantly more cardioprotective than bethanechol in both NTR and SHR hearts (P < .05 and P < .001, respectively). This result suggests that adenosine buildup is more important than muscarinic receptor stimulation as a mechanism of the protection afforded by ischemic preconditioning.
心脏手术患者中慢性高血压的发生率表明,如果能同时保护慢性高血压心肌,那么保护正常血压心肌的实验性疗法将更具临床相关性。我们在正常血压(NTR)和自发性高血压(SHR)的离体Sprague-Dawley大鼠心脏中,测试了三种保护正常血压心肌免受缺血性损伤的实验性疗法的有效性。比较了缺血预处理、腺苷预处理、氨甲酰甲胆碱预处理和未处理的NTR和SHR离体大鼠心脏中,缺血后ATP、左心室舒张末期压力、发展压力、左心室dp/dt负值和正值(-dP/dt和+dP/dt)以及冠状动脉血流量(CF)的恢复情况。通过与在体外维持相同时间但未遭受缺血损伤的NTR和SHR心脏进行比较,评估时间对我们实验准备的影响(每组N = 7)。预处理、腺苷和氨甲酰甲胆碱均显著改善了NTR和SHR心脏中ATP、左心室舒张末期压力、发展压力、-dP/dt、+dP/dt和冠状动脉血流量的恢复情况(与未处理组相比,P < 0.001,所有比较)。虽然SHR心脏中的恢复不那么明显,但这些结果表明,保护正常血压心肌的实验性疗法也能保护慢性高血压心肌。腺苷和缺血预处理的效果几乎相同,在NTR和SHR心脏中,这两种治疗的心脏保护作用均显著强于氨甲酰甲胆碱(分别为P < 0.05和P < 0.001)。这一结果表明,作为缺血预处理所提供保护机制的一部分,腺苷的蓄积比毒蕈碱受体刺激更为重要。